Wednesday, May 14

STUDY: First-line Tysabri (natalizumab) in multiple sclerosis: rationale, patient selection, benefits and risks

Abstract: Tysabri/Natalizumab is a highly effective disease modifying therapy for the treatment of relapsing forms of multiple sclerosis. Despite evidence to support its use as first-line therapy, risk of NTZ-associated progressive multifocal leukoencephalopathy (PML) has largely contributed to it being relegated to a second-line position. Health professionals only